Publications by authors named "Olivier Chinot"

100Publications

A phase III double-blind placebo-controlled randomized study of dexamphetamine sulfate for fatigue in primary brain tumors patients: An ANOCEF trial (DXA).

Neurooncol Adv 2019 May-Dec;1(1):vdz043. Epub 2019 Nov 10.

AP-HP, Hôpitaux Universitaires La Pitié-Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin; Sorbonne Université, UPMC Univ Paris 06, UMR S 1127; INSERM, U 1127; CNRS, UMR 7225; ICM, Paris, France.

View Article and Find Full Text PDF
November 2019

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.

Cancer Treat Rev 2020 Jun 26;86:102017. Epub 2020 Mar 26.

Aix-Marseille University, Assistance Publique-Hopitaux de Marseille, Centre Hospitalo-Universitaire Timone, Service de Neuro-Oncologie, Marseille, France.

View Article and Find Full Text PDF
June 2020

Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.

Neurology 2020 03 6;94(10):e1027-e1039. Epub 2020 Jan 6.

From Service de Neurologie 2-Mazarin, Sorbonne Université, IHU, ICM (C. Houillier, A.A., D.D., H.D., D.G., B.A., K.H.-X.), Service d'Hématologie (S. Choquet), Service de Neuro-Radiologie (N.M.-D.), Service d'Ophtalmologie (V.T.), Service de Médecine Nucléaire (A.K.), Service de Neuro-Pathologie (K.M.), Service d'Anatomie et Cytologies Pathologiques (F.C.), Service de Radiothérapie (L.F.), Service d'Hémato-Biologie (M.L.G.-T., M.C.), and Service de Neurochirurgie (B.M., M.P.), APHP, Groupe Hospitalier Pitié-Salpêtrière, Paris; Service d'Hématologie (C. Soussain), Institut Curie, Site Saint-Cloud; Service d'Hématologie (H.G.), CHU Lyon Sud; Service d'Hématologie (P.S., A.S.), Institut Bergonié, Bordeaux; Service de Neuro-Oncologie (O. Chinot), Aix-Marseille Université, CNRS, INP, AP-HM, CHU de la Timone, Marseille; Service de Neurologie (L.T., M.B.), CHU de Nancy; Service d'Hématologie (R.H.), Inserm U1236 Université de Rennes 1 (T.L.), CHU de Rennes; Service de Neurologie (G.A.), Hôpitaux Civils, Colmar; Service d'Hématologie (G.D.), CHU de Caen; Service d'Oncologie Médical (P.A.), Institut de Cancérologie de l'Ouest, Saint Herblain; Service d'Hématologie (C.M.-C.), CHU de Clermont-Ferrand; Service de Neurologie (A.A.), CHU de Toulouse; Service d'Oncologie Hématologique et de Thérapie Cellulaire (V.D.), CHU de Poitiers, INSERM, CIC 1402, Centre d'Investigation Clinique, Université de Poitiers; Service d'Oncologie Médicale (M.F.), Institut du Cancer de Montpellier Val d'Aurelle; Service d'Hématologie (F.J.), Centre Henri Becquerel, Rouen; Service d'Hématologie (A.C.), CHU de Besançon; Service d'Hématologie (M.P.M.-M.), CHU d'Angers; Service d'Hématologie (F.M., E.B.), CHRU de Lille; Service d'Hématologie (O. Casasnovas), CHU de Dijon; Service d'Onco-Hématologie (R.G.), CHU de Grenoble; Service d'Hématologie (L.M.F.), CHU de Strasbourg; Service d'Hématologie (J.A.), CHU de Limoges; Service d'Hématologie (J.-P.M.), CHU d'Amiens; Service d'Hématologie (A.T.), CHU de Brest; Service de Neurologie (C.C.) and Service d'Hématologie (A.W.), CHU de Nîmes; Clinique Courlancy (P.C.), Reims; Service d'Hématologie (J.T.), Hôpital Cochin, APHP, Paris; Service d'Hématologie Clinique (K.L.), Centre Hospitalier, Le Mans; Service d'Hématologie (C. Serrier), Centre Hospitalier de Perpignan; Service d'Hématologie (C. Haioun), Hôpital Henri Mondor, Créteil, APHP; Service d'Hématologie Clinique (S. Chebrek), Centre Hospitalier d'Avignon; Service d'Hématologie (J.O.B.), CHU de Clermont-Ferrand; Service d'Hématologie (L.O.), Institut Universitaire du Cancer de Toulouse; Service de Neuro-Oncologie (E.T.), Aix-Marseille Univ, CNRS, INP, AP-HM, CHU de la Timone; Service d'Ophtalmologie (N.C.), Institut Curie, Université Paris V Descartes et PSL (Paris Science et Lettre), Paris; and Service d'Hématologie et Thérapie Cellulaire (E.G.), Centre d'Investigations Cliniques INSERM U1517, Centre Hospitalier Universitaire, Université de Tours, France.

View Article and Find Full Text PDF
March 2020

Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial.

Neurology 2019 11 4;93(19):e1799-e1806. Epub 2019 Oct 4.

From the General and Stereotaxic Neurosurgery Service, Neuro-oncology (E.L.R.), EA 2694-Santé Publique: Épidémiologie et Qualité des Soins (P.D.) and Onco thAI, INSERM U1189 (N.R.), Université de Lille, Research Federation (C.L.), and Department of Neurosurgery (N.R., F.D.), CHU Lille; Service de Neurologie 2-Mazarin, APHP, Sorbonne Université, IHU, ICM (C.H.), and Service de Neurologie 2-Mazarin (A.L.D.S.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Service de Neuro-oncologie (S.C.), Hospices Civils de Lyon, Hôpital Neurologique; Service de Neuro-Oncologie (O.C.), Aix-Marseille University, AP-HM, CHU Timone, Marseille, France; and Department of Neurology & Brain Tumor Center (M.W.), University Hospital and University of Zurich, Switzerland.

View Article and Find Full Text PDF
November 2019

Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis.

Int J Cancer 2020 02 29;146(3):803-809. Epub 2019 Apr 29.

Department of Neurology and Wilhelm Sander-NeuroOncology Unit, Regensburg University Hospital, Regensburg, Germany.

View Article and Find Full Text PDF
February 2020

Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy.

Eur J Nucl Med Mol Imaging 2019 03 14;46(3):537-538. Epub 2018 Dec 14.

Service de Médecine Nucléaire, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France.

View Article and Find Full Text PDF
March 2019

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

Lancet Oncol 2018 09 13;19(9):1170-1179. Epub 2018 Aug 13.

The Brain and Spine Institute (ICM), Sorbonne Université, The National Institute of Health and Medical Research (INSERM), National Centre for Scientific Research (CNRS), Public Assistance-Paris Hospitals (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France.

View Article and Find Full Text PDF
September 2018

Coping strategies and quality of life: a longitudinal study of high-grade glioma patient-caregiver dyads.

Health Qual Life Outcomes 2018 Aug 2;16(1):157. Epub 2018 Aug 2.

EA 3279 CEReSS - Health Service Research and Quality of Life Center, Aix Marseille Université, School of medicine - La Timone Medical Campus, 27 bd Jean Moulin, F-13385, Marseille, cedex 05, France.

View Article and Find Full Text PDF
August 2018

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.

Eur J Cancer 2018 09 20;101:95-104. Epub 2018 Jul 20.

Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.

View Article and Find Full Text PDF
September 2018

Differential scanning calorimetry of plasma in glioblastoma: toward a new prognostic / monitoring tool.

Oncotarget 2018 Feb 25;9(10):9391-9399. Epub 2018 Jan 25.

Aix-Marseille Université, CNRS, INP, Inst Neurophysiopathol, Faculté de Pharmacie de Marseille, 13385 Marseille, France.

View Article and Find Full Text PDF
February 2018

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.

Oncotarget 2018 Jan 4;9(6):6752-6762. Epub 2017 Dec 4.

Department of Oncology, Herlev University Hospital, Herlev and Gentofte Hospital, Copenhagen, Denmark.

View Article and Find Full Text PDF
January 2018

Clustering based on unsupervised binary trees to define subgroups of cancer patients according to symptom severity in cancer.

Qual Life Res 2018 02 8;27(2):555-565. Epub 2017 Dec 8.

EA3279 Self-perceived Health Assessment Research Unit and Department of Public Health, APHM, Aix-Marseille University, 27 bd Jean Moulin, 13385, Marseille, France.

View Article and Find Full Text PDF
February 2018

Dyadic effects of coping strategies, time perspectives, and personality on the quality of life of cancer patients and their caregivers.

Psychooncology 2018 02 6;27(2):590-599. Epub 2017 Oct 6.

EA3279, Self-perceived Health Assessment Research Unit, Aix Marseille Université, Marseille, France.

View Article and Find Full Text PDF
February 2018

Evidence-based management of adult patients with diffuse glioma - Authors' reply.

Lancet Oncol 2017 08 26;18(8):e430-e431. Epub 2017 Jul 26.

Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany; German Consortium of Translational Cancer Research, Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany.

View Article and Find Full Text PDF
August 2017

Domains of quality of life freely expressed by cancer patients and their caregivers: contribution of the SEIQoL.

Health Qual Life Outcomes 2017 May 12;15(1):99. Epub 2017 May 12.

EA3279, Self-perceived Health Assessment Research Unit, Aix Marseille Université, 27 bd Jean Moulin, Marseille, cedex 05, F-13385, France.

View Article and Find Full Text PDF
May 2017

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

N Engl J Med 2017 03;376(11):1027-1037

From Odette Cancer Centre, Sunnybrook Health Sciences Centre (J.R.P., A.S.) and Princess Margaret Cancer Centre (N.L., W.P.M.), Toronto, the Canadian Cancer Trials Group, Queens University, Kingston, ON (C.J.O., C.W., K.D.), University of Calgary, Calgary, AB (J.G.C.), University of Alberta, Edmonton (W.R.), Quality of Life Consulting, West Vancouver, BC (D.O.), Queen's University, Kingston General Hospital, Kingston, ON (J.P.R.), and Juravinski Cancer Centre, Hamilton, ON (H.H.) - all in Canada; Azienda Unità Sanitaria Locale- Istituto di Ricovero e Cura a Carattere Scientifico Istituto delle Scienze Neurologiche, Bologna (A.A.B., E.F.), and Fondazione Istituto Neurologico Carlo Besta, Milan (L. Fariselli) - both in Italy; University Hospital Gasthuisberg, Leuven, Belgium (J.M.); Peter MacCallum Cancer Centre, Melbourne, VIC (C.P.), University of Newcastle, Newcastle, NSW (M.F.), University of Queensland, Brisbane (M.F.), and Royal North Shore Hospital, Sydney (M.B.) - all in Australia; Saitama Medical University International Medical Center, Saitama, Japan (R.N.); Hôpital de la Pitié-Salpêtrière (F.L.-D., L. Feuvret), Paris, and Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Centre Hospitalier Universitaire Timone, Marseilles (O.C.) - both in France; the European Organization for Research and Treatment of Cancer, Brussels (V.G.); the Neurology Clinic, University of Heidelberg, Heidelberg, Germany (A.W., W.W.); Tauranga Hospital, Tauranga, New Zealand (M.T.); and Maastricht University Medical Center and School for Oncology and Developmental Biology, Maastricht, the Netherlands (B.G.B.).

View Article and Find Full Text PDF
March 2017

Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study.

Eur J Cancer 2017 03 28;73:30-37. Epub 2017 Jan 28.

Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Service de Neurologie, Bobigny, France; Université Paris 13, UFR de Santé, Médecine et Biologie Humaine, Bobigny, France.

View Article and Find Full Text PDF
March 2017

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O-Methylguanine-DNA Methyltransferase Biomarker Analyses.

J Clin Oncol 2017 Jan 5;35(3):343-351. Epub 2016 Dec 5.

Timothy Cloughesy, University of California, Los Angeles; Lawrence Recht, Stanford Cancer Center, Stanford; Carlos Bais, Thomas Sandmann, Jean-Marie Bruey, Hartmut Koeppen, Bo Liu, Wendy Verret, See-Chun Phan, and David S. Shames, Genentech, South San Francisco, CA; Tom Mikkelsen, Henry Ford Hospital, Detroit, MI; Gaetano Finocchiaro, Istituto Neurologico Carlo Besta, Milan; Alba A. Brandes, Azienda Unità Sanitaria Locale-Istituto di Ricovero e Cura a Carattere Scientifico Institute of Neurologic Sciences, Bologna, Italy; Cristóbal Belda-Iniesta, Centro Integral Oncológico Clara Campal, University Hospital HM Sanchinarro, Madrid; Estela Pineda, Hospital Clinic of Barcelona; Carmen Balana, Institut Català d'Oncologia Badalona Hospital Germans Trias I Pujol, Barcelona, Spain; Olivier L. Chinot, Aix-Marseille Université Assistance Publique-Hôpitaux de Marseille, Marseille, France; David R. Macdonald, London Health Sciences Centre, London, Ontario, Canada; Manfred Westphal, University Clinic Hamburg-Eppendorf, Hamburg, Germany; Kirsten Hopkins, Bristol Haematology and Oncology Centre, Bristol, United Kingdom; and Michael Weller, University Hospital Zurich, Zurich, Switzerland.

View Article and Find Full Text PDF
January 2017

Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Lancet Oncol 2016 Nov 27;17(11):1533-1542. Epub 2016 Sep 27.

Department of Medical Oncology and Cancer Centre, University Hospital Zurich, Zurich, Switzerland; Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Centre (MUMC) and GROW (School for Oncology), Maastricht, Netherlands; Department of Radiation-Oncology, MediClin Robert-Janker-Clinic, Clinical Cooperation Unit Neuro-oncology, University Bonn Medical Centre, Bonn, Germany.

View Article and Find Full Text PDF
November 2016

Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.

Neuro Oncol 2016 10 11;18(10):1434-41. Epub 2016 Aug 11.

University Medical Center, Heidelberg, Germany (W.W., M.B.); Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France (O.L.C.); Princess Margaret Hospital, * Toronto, Canada (W.M.); Regional Cancer Center Stockholm Gotland, Stockholm, Sweden (R.H.); Department of Radiation Sciences and Oncology, Umeå University, Umeå, Sweden (R.H.); The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK (F.S.); Saitama Medical University, Iruma, Saitama Prefecture, Japan (R.N.); F. Hoffmann-La Roche Ltd, Basel, Switzerland (C.R., Y.K.); University of California Los Angeles, Los Angeles, California (T.C.).

View Article and Find Full Text PDF
October 2016

Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.

Neuro Oncol 2016 09 22;18(9):1313-8. Epub 2016 Mar 22.

Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France (O.L.C.); Saitama Medical University, Saitama, Japan (R.N.); Princess Margaret Hospital, Toronto, Canada (W.M.); Regional Cancer Center Stockholm Gotland, Stockholm, Sweden (R.H.); Department of Radiation Sciences and Oncology, Umeå University, Umeå, Sweden (R.H.); The Royal Marsden NHS Foundation Trust, Surrey, UK (F.S.); University of California, Los Angeles, California, USA (T.C.); F. Hoffmann-La Roche Ltd, Basel, Switzerland (J.G., C.R., L.A.); University Medical Center, Heidelberg, Germany (W.W.).

View Article and Find Full Text PDF
September 2016

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Neuro Oncol 2016 09 6;18(9):1297-303. Epub 2016 Mar 6.

Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive

View Article and Find Full Text PDF
September 2016

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.

Neuro Oncol 2016 08 21;18(8):1146-56. Epub 2016 Feb 21.

Medical Oncology Department, Bellaria-Maggiore Hospitals, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy (A.A.B.); Hôpital Avicenne, Paris 13 University, Bobigny, France (A.F.C.); University of California San Diego Health System, La Jolla, California (S.K.); Hospital Universitario 12 de Octubre, Madrid, Spain (J.M.S.-S.); Department of Oncology, Royal North Shore Hospital, St Leonards, Australia (H.R.W.); CHU Hôspital De La Timone, Rue Saint Pierre, France (O.C.); Austin Hospital, Heidelberg, Australia (L.C.); Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Frankfurt, Germany (J.P.S.); Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany (D.C.); Antwerp University Hospital, Edegem, Belgium (P.S.); Medical Oncology, Vall d'Hebron University Hospital and Universitat Autònoma de Barcelona, Barcelona, Spain (J.R.); Eli Lilly and Company, Erl Wood, England (A.C., C.S., I.G., C.M.); Eli Lilly and Company, Indianapolis, Indiana (S.C.G., D.D., M.M.L.); Neurology Clinic, University of Heidelberg, Heidelberg, Germany (W.W.).

View Article and Find Full Text PDF
August 2016

Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.

Neuro Oncol 2016 07 24;18(7):991-1001. Epub 2016 Jan 24.

The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK (F.S.); Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France (O.L.C.); Regional Cancer Center, Stockholm-Gotland, Karolinska University Hospital, Stockholm, Sweden (R.H.); Department of Radiation Sciences and Oncology, Umeå University, Förvaltningshuset, Universitetstorget, Umeå, Sweden (R.H.); Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada (W.M.); University Medical Center and German Cancer Research Center, Heidelberg, Germany (W.W.); University of California, Los Angeles, California, USA (T.C.); Genentech Inc., South San Francisco, California, USA (S.D.); F. Hoffmann-La Roche Ltd, Basel, Switzerland (E.P., J.G.); Saitama Medical University, Saitama, Japan (R.N.).

View Article and Find Full Text PDF
July 2016

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.

J Clin Oncol 2016 Mar 19;34(7):731-9. Epub 2016 Jan 19.

Caroline Happold, Patrick Roth, Roger Stupp, and Michael Weller, University Hospital Zurich; Monika Hegi, University Hospital Lausanne, Switzerland; Thierry Gorlia, EORTC Data Centre, Brussels, Belgium; Olivier Chinot, Aix-Marseille University, Marseille, France; Mark R. Gilbert, The University of Texas MD Anderson Cancer Center, Houston, TX; L. Burt Nabors, University of Alabama at Birmingham, Birmingham, AL; Wolfgang Wick, University of Heidelberg & German Cancer Research Center, Heidelberg, Germany; Stephanie L. Pugh, NRG Oncology Statistics and Data Management Center, Philadelphia, PA; Timothy Cloughesy, UCLA Neuro-Oncology Program, Los Angeles, CA; David A. Reardon, Dana-Farber Cancer Institute, Boston, MA; James R. Perry, University of Toronto, Toronto, Ontario, Canada; and Minesh P. Mehta, University of Maryland, Baltimore, MD.

View Article and Find Full Text PDF
March 2016

MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma.

Neuro Oncol 2015 Aug;17(8):1174-6

Assistance Publique Hopitaux de Marseille, Timone Hospital, Department of Neuro-Oncology, Marseille, France (E.T., P.F., M.B., C.B., O.C.); Aix-Marseille Université, CRO2, Marseille, France (E.T., F.B., O.C.); Sorbonne Universités, UMPC Univ Paris 06, Centre de Recherche de L'Institut du Cerveau et de la Moelle épinière, INSERM U1127, CNRS UMR 7225, Paris, France (M.S.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2, Paris, France (M.S.).

View Article and Find Full Text PDF
August 2015

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

J Clin Oncol 2015 Sep 29;33(25):2735-44. Epub 2015 Jun 29.

Thomas Sandmann, Richard Bourgon, Congfen Li, Samir Kharbanda, Franklin Peale, Priti Hegde, Heidi S. Phillips, and Carlos Bais, Genentech, South San Francisco; Timothy Cloughesy and Albert Lai, University of California Los Angeles, Los Angeles, CA; Josep Garcia, Nicola Moore, and Lauren E. Abrey F. Hoffmann-La Roche, Basel, Switzerland; Olivier L. Chinot, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Centre Hospitalier Universitaire Timone, Marseille, France; Wolfgang Wick, University Medical Center, Heidelberg, Germany; Ryo Nishikawa, Saitama Medical University, Saitama, Japan; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Roger Henriksson, Regional Cancer Center Stockholm, Stockholm; and Umeå University, Umeå, Sweden; and Frank Saran, Royal Marsden National Health Service Foundation Trust, Surrey, United Kingdom.

View Article and Find Full Text PDF
September 2015

Assessing the quality of life among caregivers of patients with gliomas.

Neurooncol Pract 2014 Dec 16;1(4):191-197. Epub 2014 Oct 16.

School of Medicine , Aix-Marseilles University, Marseilles, France (P.M.F., J.B., P.A.); EA3279, Self-perceived Health Assessment Research Unit , Marseilles , France (P.M.F., J.B., P.A.); Timone University Hospital, Department of Neurooncology , Marseilles , France (O.C.).

View Article and Find Full Text PDF
December 2014

Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.

J Clin Oncol 2015 Jul 26;33(19):2166-75. Epub 2015 May 26.

Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Umeå University, Umeå, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University Hospital of Heidelberg, Heidelberg, Germany; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Frank Saran, The Royal Marsden National Health Service Foundation Trust, Surrey, United Kingdom; Ryo Nishikawa, Saitama Medical University, Saitama, Japan; Magalie Hilton, F. Hoffmann-La Roche, Basel, Switzerland; Olivier L. Chinot, Service de Neuro-Oncologie, Aix-Marseille University, Assistance Publique- Hôpitaux de Marseille, Centre Hospitalier Universitaire Timone, Marseille, France.

View Article and Find Full Text PDF
July 2015

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.

Neuro Oncol 2015 Jul 9;17(7):1007-15. Epub 2015 Feb 9.

Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.); Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.); Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.); Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche Ltd, Basel, Switzerland (J.T.).

View Article and Find Full Text PDF
July 2015

Cilengitide in glioblastoma: when did it fail?

Authors:
Olivier L Chinot

Lancet Oncol 2014 Sep 19;15(10):1044-5. Epub 2014 Aug 19.

Aix-Marseille University, AP-HM, Department of Neuro-Oncology, CHU Timone, 13005 Marseille, France. Electronic address:

View Article and Find Full Text PDF
September 2014

Predictive biomarkers investigated in glioblastoma.

Expert Rev Mol Diagn 2014 Sep 5;14(7):883-93. Epub 2014 Aug 5.

AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 47-83, Boulevard de l'Hôpital, 75013 Paris, France.

View Article and Find Full Text PDF
September 2014

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

Lancet Oncol 2014 Aug;15(9):e395-403

Department of Neurooncology, Neurology Clinic & National Center for Tumor Diseases, University Hospital Heidelberg, Germany; German Consortium of Translational Cancer Research, Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany.

View Article and Find Full Text PDF
August 2014

Bing-Neel syndrome: a cerebral Richter syndrome?

Neurol India 2014 Mar-Apr;62(2):229-30

Departement of Neuro-Oncology, APHM, Timone Hospital, 13005; Departement of Hematology, Paoli Calmettes Institute, 13273, cedex9, Marseille, France.

View Article and Find Full Text PDF
August 2014

An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas.

Biomed Res Int 2014 2;2014:282815. Epub 2014 Apr 2.

ANOCEF (Association des Neuro-Oncologues d'Expression Française (French Speaking NeuroOncologists' Association)), France ; Service de Neuro-oncologie, Hôpital Neurologique, Hospices Civils de Lyon, 59 Boulevard Pinel, 69394 Lyon Cedex 3, Lyon, France ; Université de Lyon, Claude Bernard Lyon 1, Lyon, France ; Lyon Neuroscience Research Center, INSERM U1028/CNRS UMR 5292, Lyon, France.

View Article and Find Full Text PDF
February 2015

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

N Engl J Med 2014 Feb;370(8):709-22

From Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Service de Neuro-Oncologie, Centre Hospitaliere Universitaire Timone, Marseille (O.L.C.), UFR de Santé, Médecine et Biologie Humaine, Bobigny (A.F.C.), and Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Avicenne, Service de Neurologie, Université Paris 13 (A.F.C.), and AP-HP, Université Pierre-et-Marie-Curie, Group Hospitalier Pitié-Salpêtrière (K.H.-X.), Paris - all in France; University Hospital of Heidelberg, Department of Neurooncology, and German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany (W.W.); Princess Margaret Hospital, Toronto (W.M.), and McGill University, Montreal (P.K.) - both in Canada; Regional Cancer Center, Stockholm Gotland, Karolinska, Stockholm, and the Department of Radiation Sciences and Oncology, Umeå University, Umeå - both in Sweden (R.H.); the Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom (F.S.); Saitama Medical University, Saitama, Japan (R.N.); Oncology Institute "Ion Chiricuta," Cluj-Napoca, Romania (D.C.); Medical Oncology Department, Azienda Unità Sanitaria Locale, Bologna, Italy (A.A.B.); F. Hoffmann-La Roche, Basel, Switzerland (M.H., L.A.); and University of California, Los Angeles, Los Angeles (T.C.).

View Article and Find Full Text PDF
February 2014

Ex vivo cultures of glioblastoma in three-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening.

Exp Cell Res 2014 Feb 16;321(2):99-108. Epub 2013 Dec 16.

Aix Marseille Université, Faculté de Médecine de la Timone, 27 boulevard Jean Moulin, 13284 Marseille, France; CRO2, UMR 911, Faculté de Médecine de la Timone, 27 boulevard Jean Moulin, 13284 Marseille Cedex, France; INSERM, U911, 13005 Marseille, France; Timone Hospital, 264 Rue Saint Pierre, 13385 Marseille Cedex 5, France; APHM, Timone Hospital, Department of Pathology, 13005 Marseille, France.

View Article and Find Full Text PDF
February 2014

High-grade glioma in elderly patients: can the oncogeriatrician help?

Clin Interv Aging 2013 6;8:1617-24. Epub 2013 Dec 6.

Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.

View Article and Find Full Text PDF
August 2014

Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.

Neuro Oncol 2014 May 18;16(5):662-70. Epub 2013 Dec 18.

AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France (G.R.B., C.D., A.I.); Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière, Paris, France (A.I., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuro-radiologie, Paris, France (N.M.-D.); Service de Santé des Armées, Hôpital d'Instruction des Armées, Paris, France (M.L.); Programme Carte d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France (E.L.); AP-HM, Hôpital de la Timone, Service de Neuro-Oncologie, Marseille , France (O.C.); CHU Bordeaux, Hôpital Pellegrin, Service de Neurochirurgie, Bordeaux, France (H.L.); Hospices Civils de Lyon, Hôpital Pierre Wertheimer, Service de Neuro-Oncologie, Bron, France (J.H., F.D.); INSERM U1028, CNRS UMR5292, Bron, France (J.H., F.D.); CHU Lille, Hôpital Roger Salengro, Clinique de Neurochirurgie, Lille, France (C.R.); Institut Claudius Regaud, Département de Radiothérapie, Toulouse, France (E.M.); AP-HM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Université de la Méditerranée, Aix-Marseille, Faculté de Médecine La Timone, Marseille, France (D.F.B.).

View Article and Find Full Text PDF
May 2014

Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.

Neuro Oncol 2014 Mar 9;16(3):392-9. Epub 2013 Dec 9.

Aix-Marseille Université, INSERM CRO2, Marseille, France (E.T., F.B., D.F.-B., L.O., O.C.); Assistance Publique-Hôpitaux de Marseille (AP-HM), CHU Timone, Service de Neuro-Oncologie, Marseille, France (E.T., M.B., M.M., C.B.); Aix-Marseille Université, Public Health Research Unit-EA3279 AP-HM, Marseille, France (A.L.); Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Avicenne, Service de Neurologie, Bobigny, France (A.C.); Université Paris Descartes, Laboratoire de Recherches Biochirurgicales, Hôpital Européen Georges Pompidou, Paris, France (A.C.); INSERM U 975, CNRS UMR 7225, Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moëlle Épinière UMR-S975, Paris, France (M.S.); AP-HP, Service Neurologie 2, Groupe Hospitalier Pitié-Salpêtrière, Paris, France (M.S.); AP-HM, CHU Timone, Service de Neurochirurgie, Marseille, France (P.M.); AP-HM, CHU Timone, Service d'Anatomopathologie, Marseille, France (D.F.-B.); CHU Nord, Laboratoire de Transfert, Marseille (L.O.).

View Article and Find Full Text PDF
March 2014

Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.

Curr Neurol Neurosci Rep 2013 May;13(5):347

Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, 264 Rue Saint Pierre, 13005, Marseille, France.

View Article and Find Full Text PDF
May 2013

Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.

Authors:
Olivier L Chinot

Expert Rev Anticancer Ther 2012 Nov;12(11):1413-27

Aix-Marseille University, Assistance Publique-Hopitaux de Marseille, Centre Hospitalo-Universitaire Timone, Service de Neuro-Oncologie, 13008 Marseille, France.

View Article and Find Full Text PDF
November 2012

Recent trends in epidemiology of brain metastases: an overview.

Anticancer Res 2012 Nov;32(11):4655-62

AP-HM, Timone Hospital, Departement of Neuro-oncology and Neuro-surgery, Marseille, France.

View Article and Find Full Text PDF
November 2012

Association of carcinoid tumor and low grade glioma.

World J Surg Oncol 2012 Nov 8;10:236. Epub 2012 Nov 8.

Département d'Oncologie Médicale, Institut Paoli-Calmettes, 232 Boulevard Ste Marguerite, 13009 Marseille, France.

View Article and Find Full Text PDF
November 2012

Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.

J Neurooncol 2012 Nov 14;110(2):205-13. Epub 2012 Aug 14.

Service d'Anatomie Pathologique et de Neuropathologie, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, 13000, Marseille, France.

View Article and Find Full Text PDF
November 2012